Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept injection before pterygium surgery
IRCT20260422069131N1Phase 2Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aflibercept in pterygium (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Immunohistochemical expression of VEGF protein in pterygium tissue, Immunohistochemical expression of Ki-67 protein in pterygium tissue and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
aflibercept
03
Conditions
pterygium
Beyond the preview
Go deeper on IRCT20260422069131N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260422069131N1.